Monoclonal antibody therapy for classical Hodgkin lymphoma

8531 (2009). Monoclonal antibody therapy for classical Hodgkin lymphoma Review: Clinical Trial Outcomes future science groupClin. Invest. (2013) 3(9)90932 Thertulien R, Frankel AE, Evens AM et al. APhase I, open-label, dose-escalation,multidose study of MDX-1401 (defucosylatedhuman antiCD30 monoclonal antibody) inpatients with CD30-positive refractory/relapsed Hodgkin’s lymphoma. Presented at:AACR Meeting. Denver, CO, USA, 18–22April 2009 (Abstract 1227). 33 Blum KA, Jung SH, Johnson J L et al.Serious pulmonary toxicity in patients withHodgkin’s lymphoma with SGN-30,gemcitabine, vinorelbine, and liposomaldoxorubicin is associated with anFcgRIIIa-158 V/F polymorphism Ann.Oncol. 21, 2246–2254 (2010). 34 Schnell R, Staak O, Borchmann P et al. APhase I study with an anti-CD30 ricinA-chain immunotoxin (Ki-4.dgA) in patientswith refractory CD30+ Hodgkin’s and non-Hodgkin’s lymphoma. Clin. Cancer Res. 8(6),1779–1786 (2002). 35 Francisco JA, Cerveny CG, Meyer DL et al.cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate withpotent and selective antitumor activity. Blood102(4), 1458–1465 (2003). 36 Hamblett KJ, Senter PD, Chace DF et al.Effects of drug loading on the antitumoractivity of a monoclonal antibody drugconjugate. Clin. Cancer Res. 10, 7063–7070(2004). 37 Younes A, Bartlett NL, Leonard JP et al.Brentuximab vedotin (SGN-35) for relapsedCD30-positive lymphomas. N. Engl. J. Med.363, 1812–1821 (2010). 38 Fanale MA, Forero-Tores A, Rosenblatt JDet al. A Phase I weekly dosing study ofbrentuximab vedotin in patients with relapsed/refractory CD30-positivehematologic malignancies. Clin. Cancer Res.